Raltegravir Attenuates Experimental Pulmonary Fibrosis In Vitro and In Vivo
Open Access
- 20 August 2019
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 10, 903
Abstract
Raltegravir, an inhibitor of human immunodeficiency virus-1 (HIV-1) integrase, has been used to treat HIV/acquired immunodeficiency syndrome; however, its therapeutic effects on pulmonary fibrosis have not been investigated. In this study, the in vitro effects of raltegravir (RAV) on transforming growth factor beta 1 (TGF-β1)-induced pulmonary fibrosis on L929 mouse fibroblasts were investigated. In addition, the effects of RAV on an in vivo pulmonary fibrosis model induced by intratracheal instillation of bleomycin were investigated. The proliferation of L929 cells was inhibited after RAV treatment. Meanwhile, the in vitro and in vivo protein expression of nucleotide-binding oligomerization domain-like receptor 3 (NLRP3), high-mobility group box 1 (HMGB1), toll-like receptor 4 (TLR4), prolyl hydroxylase domain protein 2, phosphorylated nuclear factor-κB (p-NF-κB), hypoxia-inducible factor-1α (HIF-1α), collagens I and III was reduced relative to TGF-β1 or the bleomycin group. Raltegravir ameliorated pulmonary fibrosis by reducing the pathology score, collagen deposition, and expression of α-smooth muscle actin, NLRP3, HMGB1, TLR4, inhibitor of kappa B, p-NF-κB, HIF-1α, collagen I, and collagen III. The results of this study demonstrate that RAV attenuated experimental attenuates pulmonary fibrosis by inhibiting NLRP3 activation.Keywords
This publication has 40 references indexed in Scilit:
- High Mobility Group Box-1 Promotes the Proliferation and Migration of Hepatic Stellate Cells via TLR4-Dependent Signal Pathways of PI3K/Akt and JNKPLOS ONE, 2013
- The Role of Toll-like Receptors in Age-Associated Lung DiseasesThe Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2012
- Fibroblasts and Myofibroblasts: What Are We Talking About?Journal of Cardiovascular Pharmacology, 2011
- Gradual Increase of High Mobility Group Protein B1 in the Lungs after the Onset of Acute Exacerbation of Idiopathic Pulmonary FibrosisPulmonary Medicine, 2011
- Reactive Oxygen Species Are Required for Maintenance and Differentiation of Primary Lung Fibroblasts in Idiopathic Pulmonary FibrosisPLOS ONE, 2010
- Prevention of HIV Protease Inhibitor-Induced Dysregulation of Hepatic Lipid Metabolism by Raltegravir via Endoplasmic Reticulum Stress Signaling PathwaysThe Journal of Pharmacology and Experimental Therapeutics, 2010
- Hypoxia-induced Phenotypic Switch of Fibroblasts to Myofibroblasts through a Matrix Metalloproteinase 2/Tissue Inhibitor of Metalloproteinase–mediated Pathway: Implications for Venous Neointimal Hyperplasia in Hemodialysis AccessJournal of Vascular and Interventional Radiology, 2010
- Differential Role of the Fas/Fas Ligand Apoptotic Pathway in Inflammation and Lung Fibrosis Associated with Reovirus 1/L-Induced Bronchiolitis Obliterans Organizing Pneumonia and Acute Respiratory Distress SyndromeThe Journal of Immunology, 2009
- NLRP3 (NALP3, Cryopyrin) Facilitates In Vivo Caspase-1 Activation, Necrosis, and HMGB1 Release via Inflammasome-Dependent and -Independent PathwaysThe Journal of Immunology, 2009
- Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary FibrosisPLOS Medicine, 2005